About the CVR

CVR Development

The Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota led CVR development, with funding from the Bill & Melinda Gates Foundation and The Rockefeller Foundation. CVR steering group and taskforce members contributed to the development of the CVR by participating in workgroup calls regarding specific topic areas and/or reviewing written drafts of one or more sections of the document.

 

Steering Group Members

Ralph Baric, PhD, University of North Carolina, USA

Norman Baylor, PhD, Biologics Consulting Group, USA

Bruce Gellin, MD, MPH, The Rockefeller Foundation, USA

Jennifer Gordon, PhD, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health, USA

Rosalind Hollingsworth, PhD, Bill & Melinda Gates Foundation, USA

Michael Osterholm, PhD, MPH, CIDRAP, University of Minnesota, USA

Stanley Perlman, MD, PhD, University of Iowa, USA

Helen Rees, MB BCHIR (CANTAB), MA (CANTAB), MRCGP, DCH, DSc Medicine (hc), Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, South Africa

Melanie Saville, MBBS, MSc, Coalition for Epidemic Preparedness Innovations (CEPI), UK

Charlotte Weller, PhD, Wellcome Trust, UK

 

Taskforce Members

Galit Alter, PhD, Moderna, USA

Dan Barouch, MD, PhD, Beth Israel Deaconess Medical Center, USA

Seth Berkley, MD, Gavi, the Vaccine Alliance, Switzerland

Pamela J. Bjorkman, PhD, California Institute of Technology, USA

Luciana Borio, MD, Council on Foreign Relations, USA

Marco Cavaleri, PhD, European Medicines Agency, Netherlands

Rachel K. Chikwamba, PhD, MBA, Council for Scientific and Industrial Research, South Africa

Christopher Chiu, BMBch, PhD, Imperial College London, UK

Cheryl Cohen, MD, PhD, National Institute of Communicable Diseases; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, South Africa

Christopher da Costa, MD, PhD, CEPI, USA

Mark B. Feinberg, MD, PhD, International AIDS Vaccine Initiative, USA

Peter B. Gilbert, PhD, Fred Hutchinson Cancer Center, USA

Jonathan Heeney, DVM, PhD, University of Cambridge, UK

Eric Karikari-Boateng, MPharm, Ghana Food and Drugs Authority, Ghana

Wayne Koff, PhD, Human Immunome Project, USA

Marion Koopmans, DVM, PhD, Erasmus University, Netherlands

Philip Krause, MD, MBA, Consultant (formerly with the US Food and Drug Administration [FDA]), USA

Teresa Lambe, PhD, Oxford University, UK

Shabir Madhi, PhD, University of the Witwatersrand, South Africa

Jason McLellan, PhD, University of Texas at Austin, USA

Helen McShane, FRCP, PhD, FMedSci, Oxford University, UK

Kayvon Modjarrad, MD, PhD, Walter Reed Army Institute of Research (during CVR development; no with Pfizer Inc.), USA

Penny Moore, PhD, University of the Witwatersrand, South Africa

Peter Openshaw, MD, PhD, Imperial College London, UK

Peter Paradiso, PhD, Paradiso Biologics Consulting, USA

Malik Peiris, MBBS, DPhil, University of Hong Kong, China

Stanley Plotkin, MD, University of Pennsylvania, USA

Gregory A. Poland, MD, MACP, FRCP (London), Mayo Vaccine Research Group; Mayo Clinic, USA

Andrew J. Pollard, MBBS, PhD, Oxford Vaccine Group, University of Oxford; NIHR Oxford Biomedical Research Center, Oxford, UK

Stacey Schultz-Cherry, PhD, St. Jude Children’s Research Hospital, USA

Biotumelo Semete-Makokotlela, PhD, South African Health Products Regulatory Authority, South Africa

Alex Sigal, PhD, African Research Institute, South Africa

Kanta Subbarao, MBBS, World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Australia

Eric Topol, MD, Scripps Research, USA

Linfa Wang, PhD, Duke Global Health Institute, Duke-NUS Medical School, Singapore

Daniela Weiskopf, PhD, La Jolla Institute for Immunology, USA

E. John Wherry, PhD, University of Pennsylvania, USA

Michael Worobey, DPhil, University of Arizona, USA

 

CIDRAP Contributing Authors

Cory Anderson, MPH, CIDRAP, University of Minnesota, USA

Richard Danila, PhD, MPH, Epidemiology Consultant, USA

Eve Lackritz, MD, CIDRAP, University of Minnesota, USA

Tabitha Leighton Kazaglis, MPH, CIDRAP, University of Minnesota, USA

Anje Mehr, MPH, CIDRAP, University of Minnesota, USA

Kristine Moore, MD, MPH, CVR Project Director, CIDRAP, University of Minnesota, USA

Julie Ostrowsky, MSc, CIDRAP, University of Minnesota, USA

Angela Ulrich, PhD, MPH, CIDRAP, University of Minnesota, USA

 

CIDRAP Editorial/Design Staff

Elise Holmes, MPP, CIDRAP, University of Minnesota, USA

Marty Swain, CIDRAP, University of Minnesota, USA

Jim Wappes, CIDRAP, University of Minnesota, USA

 

The findings and conclusions contained within are those of the authors and do not necessarily reflect the positions or policies of the Bill & Melinda Gates Foundation and The Rockefeller Foundation.